Department of Integrated Biomedical Science & Soonchunhyang Institute of Medi-Bio Science (SIMS), Soonchunhyang University, 25 Bongjeong-ro Dongnam-gu, Cheonan 31151, Korea, Tel: +82-41-413-5028, Fax: +82-41-413-5006, E-mail: [email protected] Copyright 2026 Korean Endocrine Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited
Therefore, PYY (3-36) not only reduces body weight by decreasing food intake through the CNS but also contributes to weight loss by regulating the gut microbiota and increasing the secretion of beneficial intestinal hormones
Clinicians should measure albumin before initiating therapy and recheck it at each monitoring visit
To use it, you add bacteriostatic water
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial Multi-receptor agonists that target the glucagon, glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide 1 (GLP-1) receptors may improve outcomes in type 2 diabetes because this condition is linked to hyperglycemia and obesity